Disease, Disability, and Injury Prevention and Control Special Emphasis Panels (SEP): Risk Factors for Birth Defects, Request for Application (RFA) DD 07-001, 34692 [E7-12222]
Download as PDF
<![CDATA[
34692
Federal Register / Vol. 72, No. 121 / Monday, June 25, 2007 / Notices
of screening to improve outcomes for
women exposed to IPV.
Based on the recommendations of a
recent expert panel, in order to provide
this evidence we are proposing to
conduct a randomized controlled trial.
The trial will recruit 3680 women in a
public obstetrics, gynecology, and
family planning clinic. Women
attending this clinic tend to be African
American and of lower socioeconomic
status. For this study (the Main Study),
women will be randomly allocated to
one of three arms: (1) Screened for IPV,
and if disclosing IPV, provided
information on available IPV services;
(2) not screened and all receiving
information on available IPV services; or
(3) a control group that will not be
screened nor receive information on
available IPV services. All three arms
will be assessed with a self-report
measure for mental health, disability,
and quality of life at baseline utilizing
an audio-computer-assisted structured
interview (A–CASI) and at a 12-month
follow-up utilizing a computerizedassisted telephone interview (CATI). A
pretest with 196 women in this same
clinic will be conducted to test the
enrollment, randomization, interview,
and follow-up procedures; provide
estimates for outcome measures and a
potential mediator of outcomes (contact
of IPV services); and establish the
concordance between measures used at
baseline (in the clinic) and at a oneweek follow-up over the phone. The
study arms of the Pretest, which vary
slightly from those of the Main Study,
are designed to accomplish these
intermediate objectives. The results will
be used to refine the measures,
procedures, and sample size
requirements for the Main Study. The
results from the Main Study, the
Randomized Controlled Trial, will guide
CDC as well as other governmental
agencies, professional and health care
organizations, and women’s advocate
groups in formulating its
recommendations and policies
regarding routine screening.
There are no costs to respondents
other than their time to participate in
the survey. The total estimated
annualized burden hours are 717.7.
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
Respondents
Potential Eligibility for Pretest ......................................................................................................
Pretest Baseline Participants .......................................................................................................
Pretest Follow-up Participants .....................................................................................................
Potential Eligibility for Main Study ...............................................................................................
Main Study Baseline Participants ................................................................................................
Main Study Follow-up Participants ..............................................................................................
Dated: June 19, 2007.
Maryam I. Daneshvar,
Acting Reports Clearance Officer, Centers for
Disease Control and Prevention.
[FR Doc. E7–12241 Filed 6–22–07; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
sroberts on PROD1PC70 with NOTICES
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panels (SEP): Risk Factors
for Birth Defects, Request for
Application (RFA) DD 07–001
In accordance with Section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the following meeting:
Time and Date: 9 a.m.–5 p.m., August
1, 2007 (Closed).
Place: Teleconference.
Status: The meeting will be closed to
the public in accordance with
provisions set forth in Section 552b(c)
(4) and (6), Title 5 U.S.C., and the
Determination of the Director,
Management Analysis and Services
VerDate Aug<31>2005
23:08 Jun 22, 2007
Jkt 211001
Office, CDC, pursuant to Public Law 92–
463.
Matters To Be Discussed: The meeting
will include the review, discussion, and
evaluation of applications received in
response to ‘‘Risk Factors for Birth
Defects,’’ RFA DD 07–001.
Contact Person for More Information:
Juliana Cyril, Ph.D., Scientific Review
Administrator, Office of Public Health
Research, CDC, 1600 Clifton Road, NE.,
Mailstop D72, Atlanta, GA 30333,
Telephone 404–639–4639.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both CDC
and the Agency for Toxic Substances
and Disease Registry.
Dated: June 18, 2007.
Elaine L. Baker,
Acting Director, Management Analysis and
Services Office, Centers for Disease Control
and Prevention.
[FR Doc. E7–12222 Filed 6–22–07; 8:45 am]
BILLING CODE 4163–18–P
PO 00000
Frm 00030
Fmt 4703
Sfmt 4703
Number of
responses per
respondents
210
196
176
4600
3680
2580
Average
burden per
response
(in hours)
1
1
1
1
1
1
1/60
15/60
12/60
1/60
17/60
22/60
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Proposed Collection; Comment
Request; Graduate Student Training
Program Application
SUMMARY: In compliance with the
requirement of Section 3506(c)(2)(A) of
the Paperwork Reduction Act of 1995,
for opportunity for public comment on
proposed data collection projects, the
Graduate Partnerships Program/OITE/
OIR/OD, the National Institutes of
Health (NIH) will publish periodic
summaries of proposed projects to be
submitted to the Office of Management
and Budget (OMB) for review and
approval.
Proposed Collection
Title: Graduate Student Training
Program Application. Type of
Information Collection Request:
Revision. Form Number: 0925–0501.
Expiration Date: November 30, 2007.
Need and Use of Information Collection:
The information gathered in the
Graduate Student Training Program
application will enable the evaluation
and identification of graduate students
wishing to perform part or all of their
PhD dissertation research within the
E:\FR\FM\25JNN1.SGM
25JNN1
]]>Agencies
[Federal Register Volume 72, Number 121 (Monday, June 25, 2007)]
[Notices]
[Page 34692]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-12222]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Disease, Disability, and Injury Prevention and Control Special
Emphasis Panels (SEP): Risk Factors for Birth Defects, Request for
Application (RFA) DD 07-001
In accordance with Section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), the Centers for Disease Control and
Prevention (CDC) announces the following meeting:
Time and Date: 9 a.m.-5 p.m., August 1, 2007 (Closed).
Place: Teleconference.
Status: The meeting will be closed to the public in accordance with
provisions set forth in Section 552b(c) (4) and (6), Title 5 U.S.C.,
and the Determination of the Director, Management Analysis and Services
Office, CDC, pursuant to Public Law 92-463.
Matters To Be Discussed: The meeting will include the review,
discussion, and evaluation of applications received in response to
``Risk Factors for Birth Defects,'' RFA DD 07-001.
Contact Person for More Information: Juliana Cyril, Ph.D.,
Scientific Review Administrator, Office of Public Health Research, CDC,
1600 Clifton Road, NE., Mailstop D72, Atlanta, GA 30333, Telephone 404-
639-4639.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register notices pertaining to
announcements of meetings and other committee management activities,
for both CDC and the Agency for Toxic Substances and Disease Registry.
Dated: June 18, 2007.
Elaine L. Baker,
Acting Director, Management Analysis and Services Office, Centers for
Disease Control and Prevention.
[FR Doc. E7-12222 Filed 6-22-07; 8:45 am]
BILLING CODE 4163-18-P
